

Matthew H Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4204158/publications.pdf>

Version: 2024-02-01

45
papers

2,962
citations

257101

24
h-index

253896

43
g-index

47
all docs

47
docs citations

47
times ranked

3762
citing authors

#	ARTICLE	IF	CITATIONS
1	Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury. <i>Kidney International</i> , 2022, 101, 79-91.	2.6	15
2	Gene therapy for kidney disease: targeting cystinuria. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 175-179.	1.0	3
3	Functional analysis of the catalytic triad of the hAT-family transposase TcBuster. <i>Plasmid</i> , 2021, 114, 102554.	0.4	0
4	Cell-programmed nutrient partitioning in the tumour microenvironment. <i>Nature</i> , 2021, 593, 282-288.	13.7	491
5	Cognate restriction of transposition by <i>iggyBac</i> -like proteins. <i>Nucleic Acids Research</i> , 2021, 49, 8135-8144.	6.5	8
6	Expect the unexpected: <i>iggyBac</i> and lymphoma. <i>Blood</i> , 2021, 138, 1379-1380.	0.6	4
7	Genome Engineering Renal Epithelial Cells for Enhanced Volume Transport Function. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 17-26.	1.0	7
8	Structural basis of seamless excision and specific targeting by <i>iggyBac</i> transposase. <i>Nature Communications</i> , 2020, 11, 3446.	5.8	53
9	Metformin and Inhibition of Transforming Growth Factor-Beta Stimulate <i>In Vitro</i> Transport in Primary Renal Tubule Cells. <i>Tissue Engineering - Part A</i> , 2020, 26, 1091-1098.	1.6	4
10	CRISPR/Cas9 engineering of albino cystinuria Type A mice. <i>Genesis</i> , 2020, 58, e23357.	0.8	2
11	EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	12
12	Metabolic consequences of cystinuria. <i>BMC Nephrology</i> , 2019, 20, 227.	0.8	16
13	Direct reprogramming to human nephron progenitor-like cells using inducible <i>iggyBac</i> transposon expression of SNAI2-EYA1-SIX1. <i>Kidney International</i> , 2019, 95, 1153-1166.	2.6	21
14	Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. <i>Nature Communications</i> , 2018, 9, 1325.	5.8	16
15	Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	4
16	CRISPR/Cas9 engineering of a KIM-1 reporter human proximal tubule cell line. <i>PLoS ONE</i> , 2018, 13, e0204487.	1.1	7
17	Consider Changing the Horse for Your CAR-T?. <i>Molecular Therapy</i> , 2018, 26, 1873-1874.	3.7	4
18	Integration Mapping of <i>iggyBac</i> -Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR. <i>EBioMedicine</i> , 2018, 34, 18-26.	2.7	30

#	ARTICLE	IF	CITATIONS
19	Kidney-specific transposon-mediated gene transfer in vivo. <i>Scientific Reports</i> , 2017, 7, 44904.	1.6	23
20	Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells. <i>Nucleic Acids Research</i> , 2017, 45, 8411-8422.	6.5	37
21	Temporal self-regulation of transposition through host-independent transposase rodlet formation. <i>Nucleic Acids Research</i> , 2017, 45, 353-366.	6.5	526
22	Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 27.	6.9	42
23	Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. <i>PLoS ONE</i> , 2015, 10, e0140744.	1.1	11
24	piggyBac-ing models and new therapeutic strategies. <i>Trends in Biotechnology</i> , 2015, 33, 525-533.	4.9	101
25	Protective Role of Insulin-Like Growth Factor-1 Receptor in Endothelial Cells against Unilateral Ureteral Obstruction-Induced Renal Fibrosis. <i>American Journal of Pathology</i> , 2015, 185, 1234-1250.	1.9	39
26	Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. <i>Nucleic Acids Research</i> , 2015, 43, 1770-1782.	6.5	44
27	Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cytotherapy</i> , 2014, 16, 1257-1269.	0.3	42
28	An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. <i>FASEB Journal</i> , 2013, 27, 3753-3762.	0.2	8
29	Evaluation of Long-term Transgene Expression in piggyBac-Modified Human T Lymphocytes. <i>Journal of Immunotherapy</i> , 2013, 36, 3-10.	1.2	22
30	Hyperactive piggyBac Gene Transfer in Human Cells and In Vivo. <i>Human Gene Therapy</i> , 2012, 23, 311-320.	1.4	94
31	Loss of glutathione S-transferase A4 accelerates obstruction-induced tubule damage and renal fibrosis. <i>Journal of Pathology</i> , 2012, 228, 448-458.	2.1	28
32	Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells. <i>PLoS ONE</i> , 2012, 7, e42666.	1.1	37
33	Manipulating piggyBac Transposon Chromosomal Integration Site Selection in Human Cells. <i>Molecular Therapy</i> , 2011, 19, 1636-1644.	3.7	66
34	PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2011, 19, 2133-2143.	3.7	110
35	Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination. <i>Molecular Therapy</i> , 2011, 19, 2239-2248.	3.7	41
36	piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. <i>Human Gene Therapy</i> , 2010, 21, 427-437.	1.4	124

#	ARTICLE	IF	CITATIONS
37	Multiplexed transposon-mediated stable gene transfer in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1343-1348.	3.3	76
38	Designing and Testing Chimeric Zinc Finger Transposases. Methods in Molecular Biology, 2010, 649, 353-363.	0.4	11
39	Combining Mtor Inhibitors with Rapa-Resistant T Cells: a Two-Pronged Approach to Tumor Elimination. Blood, 2010, 116, 2853-2853.	0.6	0
40	PiggyBac Transposon-based Inducible Gene Expression In Vivo After Somatic Cell Gene Transfer. Molecular Therapy, 2009, 17, 2115-2120.	3.7	63
41	Genome-wide Mapping of PiggyBac Transposon Integrations in Primary Human T Cells. Journal of Immunotherapy, 2009, 32, 837-844.	1.2	112
42	Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes. Journal of Immunotherapy, 2009, 32, 826-836.	1.2	97
43	PiggyBac Transposon-mediated Gene Transfer in Human Cells. Molecular Therapy, 2007, 15, 139-145.	3.7	425
44	Functional zinc finger/sleeping beautytransposase chimeras exhibit attenuated overproduction inhibition. FEBS Letters, 2005, 579, 6205-6209.	1.3	49
45	Mechanisms Regulating the Cell Surface Residence Time of the β_2 -Adrenergic Receptor. Biochemistry, 2000, 39, 693-700.	1.2	37